Search
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
Miridesap
go.drugbank.com/drugs/DB13087InvestigationalMiridesap has been used in trials studying the prevention of HIV and treatment of AL amyloidosis.
Vopratelimab
go.drugbank.com/drugs/DB15378InvestigationalVopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).
Phenolsulfonphthalein
go.drugbank.com/drugs/DB13212ExperimentalPhenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories.
Tesmilifene
go.drugbank.com/drugs/DB04905InvestigationalTesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsAzelaprag
go.drugbank.com/drugs/DB19329Investigationalis under investigation in clinical trial NCT06515418 (Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide Alone in Participants With Obesity Aged 55 Years and Over
Synonyms: 2-pyrimidineethanesulfonamide, n-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4h-1,2,4-triazol-3-yl)-.alpha.,.beta.,5-trimethyl-, (.alpha.s,.beta.r)-PH-284
go.drugbank.com/drugs/DB05452ExperimentalPH-284 belongs to a new family of new chemical entities called vomeropherins. … PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients.
SSR-126517E
go.drugbank.com/drugs/DB05362ExperimentalSSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
PA-1050040
go.drugbank.com/drugs/DB06039ExperimentalPA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.